Bontiv750 mg+50 mg

Bontiv 750 mg+50 mg is a fixed-dose combination used for the symptomatic management of osteoarthritis (OA), most commonly of the knee and hip.

• Guideline/market-supported use: Bontiv 750 mg+50 mg is used as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA)-type combination for relief of pain and stiffness of osteoarthritis. Diacerein is authorised in a number of countries (with restricted use in the EU, limited to hip/knee OA) for this purpose; glucosamine sulfate is authorised as a medicinal product for osteoarthritis symptom relief in some regions (e.g. parts of Europe), while it is sold as a dietary supplement in others (e.g. the United States), where evidence of benefit is considered modest and inconsistent.
• Adjunct use: Bontiv 750 mg+50 mg is generally used as an adjunct to standard first-line measures (weight control, physiotherapy/exercise, and short-term analgesics/NSAIDs when required), not as a substitute for them.
• Off-label/limited-evidence use: Use in other joint conditions (e.g. as a supportive measure in rheumatoid arthritis or generalized bone/joint discomfort) is not well established by controlled trials and should be considered off-label; it should only be used for this purpose on a physician's specific advice.

Bontiv 750 mg+50 mg has a slow onset of action (clinical benefit is usually assessed after several weeks), so it is not intended for acute pain relief.

Each film-coated tablet of Bontiv 750 mg+50 mg typically contains Glucosamine Sulphate 750 mg (as glucosamine sulfate potassium chloride/sodium chloride complex) and Diacerein 50 mg. Strength and exact salt form may vary slightly by manufacturer/brand — always check the product label.

Bontiv 750 mg+50 mg combines two agents with complementary actions in osteoarthritis: diacerein, an anthraquinone derivative that reduces production and activity of interleukin-1 (IL-1), a key mediator of cartilage breakdown and joint inflammation; and glucosamine sulphate, a naturally occurring amino sugar that is a building block of cartilage glycosaminoglycans and proteoglycans.

Unlike NSAIDs, Bontiv 750 mg+50 mg does not significantly inhibit prostaglandin (cyclo-oxygenase) synthesis, so it is generally better tolerated on the stomach, though it carries its own distinct tolerability concerns (notably diarrhea) discussed under Side Effects and Precautions.

Bontiv 750 mg+50 mg belongs to the combination anti-osteoarthritic drug class: an Interleukin-1 (IL-1) inhibitor (diacerein) combined with a Symptomatic Slow-Acting Drug for Osteoarthritis / cartilage-matrix substrate (glucosamine sulphate).

Pharmacodynamics

Bontiv 750 mg+50 mg acts through two complementary mechanisms:

• Diacerein and its active metabolite rhein inhibit the synthesis and activity of interleukin-1 beta (IL-1β), reducing downstream production of degradative enzymes (metalloproteinases) and pro-inflammatory mediators in cartilage and synovium. It does not inhibit cyclo-oxygenase, so it lacks the prostaglandin-mediated GI/renal effects typical of NSAIDs. Onset of clinical benefit is slow, typically evident only after several weeks of continuous use.
• Glucosamine sulphate is a natural substrate for glycosaminoglycan and proteoglycan synthesis in articular cartilage; supplementation is proposed to support cartilage matrix formation and may have a mild anti-inflammatory effect within the joint, though the magnitude of clinical benefit demonstrated in trials is modest and inconsistent.

Pharmacokinetics

Diacerein is rapidly deacetylated to its active metabolite rhein, which is highly protein-bound, metabolised in the liver, and eliminated mainly via the kidneys (as glucuronide/sulfate conjugates) — this is why hepatic and renal function are relevant to safe use. Rhein conjugates can impart a yellow/pink discoloration to urine, which is harmless. Glucosamine sulphate is absorbed from the gut, distributed to cartilage and other tissues, and excreted predominantly via the kidneys.

Take Bontiv 750 mg+50 mg tablets orally with food (e.g. with or just after a meal) to help reduce stomach upset; swallow the tablet whole with a glass of water — do not crush or chew unless the product is specifically designed for that. Take at evenly spaced times each day and continue for the duration advised by your physician.

• Antacids (aluminium/magnesium hydroxide): reduce absorption and plasma levels of the diacerein component of Bontiv 750 mg+50 mg; separate dosing by at least 2 hours.
• Laxatives and other drugs that loosen stools: concurrent use with Bontiv 750 mg+50 mg increases the risk and severity of diarrhea; avoid combining unless directed by a physician.
• Antibiotics: concurrent antibiotic use may increase the risk of diarrhea while taking Bontiv 750 mg+50 mg; monitor closely.
• Warfarin/other anticoagulants: the glucosamine component of Bontiv 750 mg+50 mg has been reported to potentiate the effect of vitamin K antagonists, increasing INR and bleeding risk; monitor INR more closely if co-administered.
• Antidiabetic drugs/insulin: glucosamine may theoretically affect blood glucose control; monitor blood glucose in people with diabetes taking Bontiv 750 mg+50 mg.
• Other hepatotoxic drugs: concurrent use of other medicines with liver-toxicity potential may add to the hepatic risk associated with the diacerein component of Bontiv 750 mg+50 mg; use together only with medical advice and liver monitoring.

The most common and dose-limiting side effect of Bontiv 750 mg+50 mg is diarrhea/loose stools (due to the diacerein component), which is usually mild-to-moderate, often occurs early in treatment, and may require dose reduction or discontinuation if severe or persistent.

• Very common/common: diarrhea, soft stools, abdominal pain, nausea, vomiting.
• Common: headache, skin rash, itching (pruritus), eczema.
• Uncommon but clinically important: elevated liver enzymes/hepatic dysfunction (see Precautions and Warnings), harmless yellow/pink discoloration of urine (from the rhein metabolite).
• Rare: severe skin/hypersensitivity reactions.

Seek prompt medical attention for persistent or severe diarrhea, signs of liver problems (yellowing of skin/eyes, dark urine unrelated to the expected harmless discoloration, unusual fatigue, right upper abdominal pain), or any severe allergic reaction while taking Bontiv 750 mg+50 mg.

Bontiv 750 mg+50 mg is contraindicated in pregnancy and during breastfeeding. Animal and human safety data for the diacerein component in pregnancy are insufficient, and both components lack established safety in this setting. Bontiv 750 mg+50 mg should not be used by pregnant or breastfeeding women; if a patient becomes pregnant while taking Bontiv 750 mg+50 mg, it should be stopped and a physician consulted promptly for alternative management of joint symptoms.

• Diarrhea: the diacerein component of Bontiv 750 mg+50 mg commonly causes diarrhea; advise patients to maintain hydration and to stop treatment and seek medical advice if diarrhea is severe, persistent, or associated with dehydration.
• Liver function: hepatic enzyme elevation and hepatotoxicity have been reported with diacerein-containing products; baseline and periodic liver function monitoring is advisable, and Bontiv 750 mg+50 mg should be stopped if signs of liver injury occur. Avoid in anyone with pre-existing liver disease (see Contraindications).
• Elderly patients: use Bontiv 750 mg+50 mg with added caution in patients over 65 years, who may be more susceptible to diarrhea and its complications (e.g. dehydration); some regulatory reviews have recommended particular caution or avoidance of diacerein-containing products in this age group.
• Shellfish allergy: the glucosamine component of Bontiv 750 mg+50 mg is often derived from shellfish (crustacean) shells; use with caution or avoid in people with known shellfish allergy, and check the product source with the pharmacist/manufacturer.
• Diabetes: monitor blood glucose more closely, as glucosamine may theoretically affect glucose control.
• Bleeding tendency/anticoagulant use: monitor for increased bleeding tendency (see Interactions).
• Renal impairment: use with caution in mild-to-moderate renal impairment (contraindicated in severe impairment — see Contraindications).
• Bontiv 750 mg+50 mg is not intended for rapid/acute pain relief; effect develops gradually over weeks.

Limited data are available on overdose with Bontiv 750 mg+50 mg. Overdose would be expected to mainly intensify known effects, particularly severe diarrhea, vomiting, and abdominal pain, with a theoretical risk of dehydration and electrolyte disturbance; effects on the liver cannot be excluded with excessive or prolonged overdosing.

There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services; supportive care (including rehydration and monitoring) will be provided by medical staff. Do not attempt specific home treatment beyond initial supportive measures (such as oral fluids) while awaiting medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: contraindicated in severe renal impairment; use with caution and medical supervision in mild-to-moderate impairment (see Contraindications, Dosage).
• Hepatic impairment: contraindicated in severe hepatic impairment or history of liver disease; periodic liver function monitoring recommended in others (see Precautions).
• Elderly (>65 years): increased caution advised due to greater susceptibility to diarrhea/dehydration (see Precautions).
• Pregnancy and lactation: contraindicated (see Pregnancy and Lactation).
• Pediatric patients: not recommended; safety and efficacy not established under 18 years (see Pediatric Use).
• Diabetics and patients on anticoagulants: require closer monitoring of blood glucose and INR/bleeding respectively (see Interactions).

Because Bontiv 750 mg+50 mg has a slow onset of symptomatic benefit, treatment is generally continued for at least 4–6 weeks before its effect is assessed, and courses of several weeks to a few months are typical for a treatment cycle. Continued use should be reassessed periodically by the prescribing physician — treatment should not be continued indefinitely without clinical review, and it should be discontinued if there is no meaningful symptomatic improvement after an adequate trial or if intolerable side effects (especially diarrhea or signs of liver problems) occur.

Bontiv 750 mg+50 mg — combination of an Interleukin-1 (IL-1) inhibitor / anthraquinone derivative (diacerein) and a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA) / cartilage-matrix substrate (glucosamine sulphate).

Bontiv 750 mg+50 mg works through two complementary mechanisms: diacerein and its active metabolite rhein suppress interleukin-1-driven cartilage-degrading enzyme activity and joint inflammation without inhibiting cyclo-oxygenase; glucosamine sulphate supplies a substrate used in synthesis of cartilage glycosaminoglycans/proteoglycans, supporting cartilage matrix maintenance. Together they are intended to provide gradual symptomatic relief in osteoarthritis rather than immediate analgesia.

The safety and efficacy of Bontiv 750 mg+50 mg in children and adolescents under 18 years have not been established, and it is not recommended for use in this age group. Osteoarthritis is uncommon in children, and Bontiv 750 mg+50 mg should only be considered in a pediatric patient under specialist advice if there is a specific, well-justified indication, which would be unusual.